NCT02128074已完成2 期
A Phase 2 Pilot Study of KRX-0502 (Ferric Citrate) in Treating Iron-deficiency Anemia in Patients With Stage 3-5 Non-dialysis Dependent Chronic Kidney Disease (NDD-CKD)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 3
- 主要终点
- Change in Hemoglobin From Baseline to the End of 8-week Treatment Period
研究概览
简要总结
The objective of the study is to evaluate the efficacy and safety of KRX-0502, administered without food, in treating iron deficiency anemia in subjects with stage 3 to 5 non-dialysis dependent chronic kidney disease (NDD-CKD).
详细描述
Previous clinical trials have tested KRX-0502 administered with food, in dialysis-dependent and NDD-CKD patients.
This clinical trial will evaluate the safety and efficacy of KRX-0502 in treating iron deficiency anemia in anemic, stage III to V NDD-CKD patients in a new dosing regimen (without food).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and non-lactating females with negative serum pregnancy test (for females of child-bearing potential) at Screening
- •Age ≥ 18 years
- •Serum ferritin ≤ 300 ng/mL and TSAT ≤ 25% at Screening
- •Hemoglobin ≥9.0 g/dL and ≤11.5 g/dL at Screening
- •eGFR <60 mL/min at Screening using the 4-variable Modification of Diet in Renal Disease (MDRD) equation
排除标准
- •Subjects receiving phosphate binder medication(s) at, or within 4 weeks prior to, screening
- •Symptomatic gastrointestinal bleeding, inflammatory bowel disease, inflammatory bowel syndrome and/or Crohn's Disease within 24 weeks prior to \ Screening
- •Evidence of acute kidney injury or requirement for dialysis within 8 weeks prior to Screening
- •Kidney transplant anticipated or start of dialysis expected within 16 weeks of Screening
- •History of hemochromatosis
- •IV iron administered within 4 weeks prior to Screening
- •Erythropoiesis-Stimulating Agent (ESA) administered within 4 weeks prior to Screening
- •Blood transfusion within 4 weeks prior to Screening
- •Receipt of any investigational drug within 4 weeks prior to Screening
- •Cause of anemia other than iron deficiency or chronic kidney disease
- •History of malignancy in the last five years
- •Active drug or alcohol dependence or abuse (excluding tobacco use) within the 12 months prior to Screening
- •Any known allergies to iron products
- •Previous intolerance to oral ferric citrate
- •Psychiatric disorder that interferes with the subject's ability to comply with the study protocol
- •Planned surgery or hospitalization during the trial
- •Any other medical condition that, in the opinion of the PI, renders the subject unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the subject
研究组 & 干预措施
KRX-0502
Experimental
KRX-0502 (ferric citrate)
干预措施: KRX-0502 (Drug)
结局指标
主要结局
Change in Hemoglobin From Baseline to the End of 8-week Treatment Period
时间窗: 8 weeks
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on DialysisIron DeficiencyIron Deficiency AnemiaNCT01736397Keryx Biopharmaceuticals149
已完成
不适用
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal DiseaseEnd-stage Renal DiseaseRenal Failure Chronic Requiring HemodialysisHyperphosphatemiaNCT00967993Keryx Biopharmaceuticals22
已完成
3 期
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKDAnemia of Chronic Kidney DiseaseNCT02268994Keryx Biopharmaceuticals234
已完成
4 期
KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)Chronic Kidney DiseasesIron Deficiency AnemiaNCT03236246Keryx Biopharmaceuticals206
已完成
3 期
A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on DialysisEnd Stage Renal DiseaseKidney FailureESRDRenal FailureHyperphosphatemiaNCT01554982Keryx Biopharmaceuticals168